2nd Structure-Based Drug Design Summit San Diego

Memo

The 2nd Structure-Based Drug Design Summit San Diego arrives at a pivotal moment for the field as AI-driven structure prediction and de novo design tools move rapidly from proof-of-concept into practical application, reshaping how structural biologists approach drug discovery. Following major investment surges into AI-enabled drug design platforms, including Isomorphic Labs' $2.1B Series B, and mounting pressure to de-risk pipelines earlier amid tightening budgets, the focus has shifted from whether to use AI to how to integrate it most effectively alongside experimental structural biology.As the industry's only West Coast-dedicated meeting focused exclusively on structure-based drug design, this summit brings together 60+ structural biologists, computational and medicinal chemists, and drug discovery leaders across pharma, biotech, and academia to tackle the field's most pressing technical bottlenecks. Discussions will explore how to characterize increasingly complex and previously "undruggable" targets, membrane proteins, GPCRs, and multi-protein complexes, integrate cryo-EM, X-ray crystallography, NMR, and AI into unified workflows, understand protein dynamics beyond static structures, and extend SBDD principles across modalities including biologics, peptides, molecular glues, and protein degraders.With a dedicated pre-conference workshop day, case study-driven presentations from West Coast leaders at companies including Gilead, Vertex, Sanofi, Eli Lilly, and Novartis, and extensive networking including speed networking, panel discussions, and roundtable feedback sessions, this is the must-attend forum to benchmark strategies, build cross-functional partnerships, and translate high-resolution structural insight into higher-quality, developable drug candidates faster and more efficiently.URLs:Tickets: https://go.evvnt.com/3853945-2?pid=5569Brochure: https://go.evvnt.com/3853945-3?pid=5569Date and Time: On Tuesday February 02, 2027 at 8:30 am to Thursday February 04, 2027 at 5:00 pmVenue details: The Westgate Hotel, 1055 Second Avenue, San Diego, California, 92101, United StatesPrices:Drug Developer Pricing* Full Access: Conference + 2 Workshops: USD 3897.00,Drug Developer Pricing* Conference Only: USD 2799.00,Academic Pricing** Full Access: Conference + 2 Workshops: USD 3297.00,Academic Pricing** Conference Only: USD 2399.00,Service Provider Pricing*** Full Access: Conference + 2 Workshops: USD 5497.00,Service Provider Pricing*** Conference Only: USD 4099.00Speakers: Mats Wikstrom, Associate Director and Group Leader, Amgen Inc., Deb Conrady, Senior Principal Scientist - Structural Biology, C4 Therapeutics Inc, Matt Bratkowski, Associate Director, Calico Life Sciences LLC, Alpay Seven, Head of Structural Biology, Deep Apple Therapeutics, Julia Dou Director, Protein Chemistry, Degron Therapeutics, Jennifer Kung, Senior Scientist, Denali Therapeutics Inc., Yu-Hua Lo, Director of CryoEM Science and Operations, Eli Lilly and Co., Elizabeth Wittenborn, Scientist - Structural Biology, Foghorn Therapeutics, Andrew Flick, Director - Chemistry, Genesis Molecular AI, Mauricio Garcia-Atance, Program Director, Hanson Wade, Alexander Taguchi, Director - Machine Learning, iBio, David C. Wright, Chief Scientific Officer, LPJP, Inc., Sumeet Salaniwal, Senior Director - Computational Chemistry and Cheminformatics, Lyterian Therapeutics, Andres Hernandez, Principal Scientist, Neomorph, Paul Rejto, Vice President - Discovery Technologies, Pfizer, James Ferguson, Staff Scientist Structural Biology, The Scripps Research Institute, Julianna Han, Senior Staff Scientist - Ward Lab, The Scripps Research Institute, Bastien Casu, Cryo-EM and TEM Specialist - Structural Biology, University of California, Irvine, Jeff Holden, Director and Head of Structural Biology, Vilya Therapeutics, Steffen Bernard, Principal Scientist, Vividion Therapeutics